

From: Geraldine MacGibbon
Sent: Wednesday, 29 June 2016 10:32 AM
To: Brian Rouliston
Subject: RE: Supply updates

Ok great, thank you – once we know about the 1mg we can put in the MSC, presume for 1 August listing?

[REDACTED]

From: Brian Rouliston
Sent: Wednesday, 29 June 2016 10:31 a.m.
To: Geraldine MacGibbon
Subject: RE: Supply updates

Yes and no – I spoke to BNM yesterday...

They have 696 packs of Stelazine 2mg on hand – exp Jan 2017.
They seem confident of getting a stock of a 1mg presentation, although this will be S29, will confirm shortly.
Stock of a 5mg is unlikely until late 2016 when a new batch is due to be manufactured. This would also be S29.

So this is not much of an update from the info in their earlier email.

From: Geraldine MacGibbon
Sent: Wednesday, 29 June 2016 10:24 a.m.
To: Brian Rouliston
Subject: RE: Supply updates

Hi Brian did you manage to get an update on this?

Thanks

G

[REDACTED]

From: Brian Rouliston
Sent: Thursday, 23 June 2016 3:17 p.m.
To: Geraldine MacGibbon
Subject: RE: Supply updates

I'll get an update from B&M. The last time I spoke to B&M they were still investigating the option out of the UK.
They did say that there was plenty of 2mg.

From: Geraldine MacGibbon
Sent: Thursday, 23 June 2016 2:35 p.m.
To: Brian Rouliston
Subject: RE: Supply updates

Hi Brian

Have you had an update on Stelazine (trifluoperazine)? One of the hospital mental health pharmacists has contacted me asking what is going on, as he had heard from a community pharmacy that it is in short supply and/or due to be discontinued.

If we need to list an S29 product for August we'll need to get on to it soon...?

Many thanks
Geraldine

From: Geraldine MacGibbon
Sent: Wednesday, 25 May 2016 4:56 p.m.
To: Brian Rouliston
Subject: RE: Supply updates

Hi

Yes lets discuss tomorrow.

[REDACTED]

From: Brian Rouliston
Sent: Wednesday, 25 May 2016 4:53 p.m.
To: Geraldine MacGibbon
Subject: FW: Supply updates

Hi Geraldine,

B&N have indicated a couple of supply issues for non-contracted products in your groups – Stelazine and [REDACTED]
There maybe solutions per Kathia's email below, when you have a moment can we quickly discuss.

Yes, this late notification is not particularly satisfactory, particularly for clinician and patients.

Brian

From: Kathia Lin [REDACTED]
Sent: Wednesday, 25 May 2016 4:22 p.m.
To: Brian Roultson
Cc: Boucher & Muir t/a Goldshield
Subject: Supply updates

Hi Brian,

We wish to advise the stock status of the following product lines:

Stelazine tablets - We currently have 742 packs of 5mg (exp Jul-16) remaining. Supplier has not been able to confirm a likely delivery time of our delayed shipment, although it appears that supply may not be forthcoming at least until the end of 2016. As wholesalers are unwilling to keep short-dated stock on shelves, we have been filling orders on a patient requirement basis. We also have plenty of 2mg stock (exp Jan-17) for alternative dispensing. Stocks of 1mg strength are also expiring in Sep-16. AMCo is now investigating supply of an alternative product out of UK. If possible, we may be able to secure access to both the 1mg and 5mg around August 2016 (yet to be confirmed, as discussions are still ongoing). If this is successful, the only route to market will be via section 29 supply. Whilst this will be inconvenient, this may be the best solution we can propose at this point in time.

[REDACTED]

Kind regards,
Kathia Lin
Business Unit Manager



Level 1, 134 Willoughby Road,
Crows Nest NSW 2065, Australia

T +612 9431 6333
F +612 9906 7147

Please send purchase orders for Australia & New Zealand to domesticorders@bmggroup.com.

The BNM Group incorporates Boucher & Muir Pty Ltd, Boucher & Muir (PNG) Ltd, Boucher & Muir (New Zealand) Ltd, Mercury Pharma (Australia), Mercury Pharma (New Zealand), eMerge Medical Pty Ltd & Southpac Healthcare Ltd. This correspondence is for the named person's use only. It may contain confidential or legally privileged information or both. No confidentiality or privilege is waived or lost by any mistransmission. If you receive this correspondence in error, please immediately delete it from your system and notify the sender. You must not disclose, copy or relay any part of this correspondence if you are not the intended recipient.

From: Kathia Lin <[REDACTED]>
Sent: Monday, 27 June 2016 7:07 PM
To: Brian Rouleston
Cc: Boucher & Muir t/a Goldshield
Subject: RE: Stelazine

Hi Brian,

We currently have 696 units of Stelazine 2mg with expiry of Jan-2017. Since the shortage of 1mg and 5mg, we've sold 116 units of the 2mg in May and 160 units during June so far. This is up from the usual average of 76 units.

With regards to s29 options, we are working with AMCo head office to secure UK stocks of the 1mg. Unfortunately there is no immediate solution for the 5mg but there is potential for a batch to be manufactured in Q4, for supply under s29.

Kind regards,

Kathia Lin
Business Unit Manager

BNI
group

Please send purchase orders for Australia & New Zealand to domesticorders@bnigroup.com.

From: Brian Rouleston <[REDACTED]>
Sent: Friday, 24 June 2016 9:25 AM
To: Kathia Lin
Cc: Abdul Azam
Subject: Stelazine

Hi Kathia

Can I get an update on the Stelazine supply issue?

As I understand it, there is plenty of 2mg and there is a potential supply of a s29 1mg and 5mg.

Kind regards,
Brian

From: Kathia Lin <[REDACTED]>
Sent: Wednesday, 25 May 2016 4:22 p.m.
To: Brian Rouleston
Cc: Boucher & Muir t/a Goldshield
Subject: Supply updates

Hi Brian,

We wish to advise the stock status of the following product lines:

Stelazine tablets – We currently have 742 packs of 5mg (exp Jul-16) remaining. Supplier has not been able to confirm a likely delivery time of our delayed shipment, although it appears that supply may not be forthcoming at least until the end of 2016. As wholesalers are unwilling to keep short-dated stock on shelves, we have been filling orders on a patient requirement basis. We also have plenty of 2mg stock (exp Jan-17) for alternative dispensing. Stocks of 1mg strength are also expiring in Sep-16. AMCo is now investigating supply of an alternative product out of UK. If possible, we may be able to secure access to both the 1mg and 5mg around August 2016 (yet to be confirmed, as discussions are still ongoing). If this is successful, the only route to market will be via section 29 supply. Whilst this will be inconvenient, this may be the best solution we can propose at this point in time.

[REDACTED]

Kathia Lin
Business Unit Manager

BNI
group

Level 1, 134 Willoughby Road,
Crows Nest NSW 2065, Australia

From: Geraldine MacGibbon
Sent: Wednesday, 10 August 2016 11:26 AM
To: Brian Rouleston
Subject: RE: Trifluoperazine -supply issues

Thanks Brian – a lot of anxious hospital mental health pharmacists at the moment about this

[SHEKAI]

From: Brian Rouleston
Sent: Tuesday, 9 August 2016 4:21 p.m.
To: Geraldine MacGibbon
Subject: RE: Trifluoperazine -supply issues

No, I'll get an update from the BNM regarding the 1mg, they were hoping to confirm a possible supply option.

From: Geraldine MacGibbon
Sent: Tuesday, 9 August 2016 12:49 p.m.
To: Brian Rouleston
Subject: FW: Trifluoperazine -supply issues

Hi Brian do you have an update on this?

Thanks
Geraldine

From: Ghada Sarah (ADHB) [REDACTED]
Sent: Tuesday, 9 August 2016 12:04 p.m.
To: Geraldine MacGibbon
Cc: Janet Mackay
Subject: Trifluoperazine -supply issues

Hi Geraldine,

Thank you for your help with my previous inquiry regarding the [REDACTED]

I am writing to inform you of trifluoperazine supply issues, in case you haven't been made aware. As far as we're aware there's no 5mg stock as all stock is now expired, 1mg stock will be expiring at the end of Sept, and 2mg will be expiring at the beginning of next year. Our clinicians have received many phone calls from community pharmacies regarding the supply issue.

Our wholesaler advised that the supplier will be bringing in a s29 alternative, however I haven't received any recent updates and I can't find anything about this issue in the schedule update/HML? Are you able to provide an update?

Thanks
Ghada

Ghada Sarah
Lead Procurement Pharmacist | Ward 41 Pharmacist | Pharmacy Department
[REDACTED] (09) 307 4949 ext [REDACTED]
Auckland District Health Board | Level 6 | Support Building | Auckland City Hospital | New Zealand

From: Geraldine MacGibbon
Sent: Friday, 12 August 2016 8:28 AM
To: Brian Roultson
Subject: FW: Stelazine

FYI – this looks pretty serious, I think we will need to take some urgent action...?

From: Andrew McKeen [mailto:]
Sent: Thursday, 11 August 2016 12:06 p.m.
To: Geraldine MacGibbon
Subject: FW: Stelazine

Hi Geraldine

This is apparently the situation at CDC Pharmaceuticals: 11 boxes of 1mg tablets (September 2016 expiry) and 30 boxes of 2mg tablets (January 2017 expiry) with no new stock expected.

With warmest regards,

Andrew McKeen
Senior Pharmacist
Hillmorton Hospital
Private Bag 4733
Christchurch
Phone (internal) [redacted] or (externally) [redacted]

From: Jacqui Lawson [redacted]
Sent: Thursday, 11 August 2016 11:59 a.m.
To: Andrew McKeen <[redacted]>
Subject: FW: Stelazine

Hi Andrew

The information below has come from one of the 2 pharmacy wholesalers in Canterbury. It looks like no more new stock is expected.

Looking forward to hearing if you have an update on the Section 29.

Jacqui

P/Code	Description	Outerpack	Cat. *In Stock **RRP	Wholesale Price
2243563	STELAZINE TABS 1MG 100 Exp - 09/16		ETH 11	\$0.00 \$10.85 Add Product added to cart
2243547	STELAZINE TABS 2MG 100 Exp - 01/17		ETH 30	\$0.00 \$16.16 Add Product added to cart
2243555	STELAZINE TABS 5MG 100 Exp - 07/16		ETH In Stock	

Jacqui Lawson | Clinical Facilitator
Pegasus Health (Charitable) Ltd
Hours of work: Mon am and Thurs all day
P: [redacted]

From: Debbie Campbell [mailto:]
Sent: Thursday, 11 August 2016 11:56 a.m.
To: Jacqui Lawson
Subject: Stelazine

Subject: Stelazine 1mg tabs 100's - Buy 1 Get 1 Free

Dear Wholesaler,

You may be aware that there has been recent stock shortage on all SKUs of Stelazine. We'd like to offer a solution to alleviate some of that pressure, in particular the demand for 2mg, which has spiked considerably since the expiry of 5mg strength.

For all remaining stock of Batch 4M8B001A which is due to expire Sep-16, we will be offering 1 free pack with every pack purchased, as a means to extend the availability of Stelazine in the market and reduce the demand for 2mg. If you receive any pharmacy requests for Stelazine 2mg, we strongly encourage 2 packs x 1mg as an alternative. This is to help prolong stock cover of the remaining inventory of 2mg, which carries a slightly longer dating of Jan-17. We will be advising the same to any pharmacy queries that come through to our office.

No additional action is required from you, as it will be processed automatically from our end. This is effective from Thursday 11th August. If you have any further questions regarding the above, please feel free to contact me.

Kind regards,
Kathia Lin
Business Unit Manager, Australasia

Hi Jaqui,
Hope this helps.

Kind regards
Deb

Deb Campbell
Buyer/Hospital Customer Service
CDC Pharmaceuticals Ltd
Napier Branch
T: 06 831 0620 ext [REDACTED]
F: 06 831 0057
E: [REDACTED]

This email or attachment(s) may contain confidential or legally privileged information intended for the sole use of the addressee(s). Any use, redistribution, disclosure, or reproduction of this message, except as intended, is prohibited. If you received this email in error, please notify the sender and erase all copies of the message, including any attachments.

Any views or opinions expressed in this email (unless otherwise stated) may not represent those of Pegasus Health Ltd.

From: Geraldine MacGibbon
Sent: Friday, 16 September 2016 10:50 AM
To: Brian Roulston
Subject: FW: Trifluoperazine -supply issues
Importance: High

Hi Brian are you able to help with a response to this?

Thanks
G

[SERIAL]

From: Ghada Sarah (ADHB) [mailto:]
Sent: Friday, 16 September 2016 9:35 a.m.
To: Geraldine MacGibbon
Subject: RE: Trifluoperazine -supply issues
Importance: High

Hi Geraldine,

We have had several more enquiries now about trifluoperazine, so I'm emailing to find out if there has been any updates? There is no stock of the 5mg, short dated stock (exp 30/9/16) of the 1mg strength & no sign of S29 stock! We have been relaying the information below but there are on-going concerns from psychiatrists that trifluoperazine is going to go completely out of stock!

Any updates would be much appreciated.

Thanks
Ghada

Ghada Sarah
Lead Procurement Pharmacist | Ward 41 Pharmacist | Pharmacy Department
☎ (09) 307 4949 ext. | Mobil: | Auckland District Health Board | Level 6 | Support Building | Auckland City Hospital | New Zealand

From: Geraldine MacGibbon [mailto:]
Sent: Thursday, 18 August 2016 9:19 a.m.
To: Ghada Sarah (ADHB)
Subject: RE: Trifluoperazine -supply issues

Hi again Ghada

The latest information I have is that the supplier has managed to secure a little more 2 mg stock and a small amount of S29 1 mg stock, which combined should get us through until the end of this year. We should have more information on supply beyond that within the next 6 weeks and I will advise to update you at that time.

Kind regards
Geraldine

From: Geraldine MacGibbon
Sent: Wednesday, 10 August 2016 11:26 a.m.
To: 'Ghada Sarah (ADHB)'
Subject: RE: Trifluoperazine -supply issues

Hi Ghada

The last I heard the supplier was trying to source an alternative (unregistered) presentation for the 1 mg and 5 mg strengths. I have asked for an update and will get back to you to confirm.

Cheers
Geraldine

From: Ghada Sarah (ADHB) [mailto:]
Sent: Tuesday, 9 August 2016 12:04 p.m.
To: Geraldine MacGibbon
Cc: Janet Mackay
Subject: Trifluoperazine -supply issues

Hi Geraldine,

Thank you for your help with my previous inquiry regarding the [REDACTED]

I am writing to inform you of trifluoperazine supply issues, in case you haven't been made aware. As far as we're aware there's no 5mg stock as all stock is now expired. 1mg stock will be expiring at the end of Sept, and 2mg will be expiring at the beginning of next year. Our clinicians have received many phone calls from community pharmacies regarding the supply issue.

Our wholesaler advised that the supplier will be bringing in a S29 alternative, however I haven't received any recent updates and I can't find anything about this issue in the schedule update/HML? Are you able to provide an update?

Thanks
Ghada

From: Brian Rouliston
Sent: Tuesday, 20 September 2016 4:14 PM
To: Geraldine MacGibbon
Subject: FW: Stelazine
Attachments: NOPC Trifluoperazine s29.pdf

Just an update – everything is one track for 1 October listing.

MSC - is with Greg for review and approval. Have given Sarah a heads up about the Imminent DA Minute for approval

Supplier - Boucher have advised that stock was released this morning. They have sent through an NOPC, including Pharmacode etc.

Schedule - Kaye is ready to set this up in the Schedule for 1 October and has notified Software vendors etc.

From: Kathia Lin [mailto:]
Sent: Tuesday, 20 September 2016 3:31 p.m.
To: Brian Rouliston
Cc: Abdul Azam
Subject: RE: Stelazine

Hi Brian,
Pharmacode came through, please see NOPC enclosed. I've backdated effective date to 12th of this month so please advise if this is not appropriate.

Thanks,

Kathia Lin
Business Unit Manager, Australasia



From: Kathia Lin
Sent: Tuesday, 20 September 2016 1:16 PM
To: 'Brian Rouliston' < >
Cc: Abdul Azam < >
Subject: RE: Stelazine

Hi Brian,

Application has just been submitted to the Guild. I'll complete NOPC as soon as Pharmacode comes through. I've just designated AMCo as the brand name in this case.

We have pro-rated the sell price so the subsidy you have suggested will be sufficient.

Thank you.

Kathia Lin
Business Unit Manager, Australasia



From: Brian Rouliston [mailto:]
Sent: Tuesday, 20 September 2016 12:43 PM
To: Kathia Lin < >
Cc: Abdul Azam < >
Subject: RE: Stelazine
Importance: High

Thanks Kathia,

Pharmacode - I've contacted Lisa Cho at the Pharmacy Guild (ph 64-4-) and she will keep a look out for your Pharmacode application and will process this ASAP.

Brand name – generally we don't use chemical names as the brand name, can we use "Boucher" or some other name as the brand name?

Brian

From: Kathia Lin [mailto:]
Sent: Tuesday, 20 September 2016 1:47 p.m.
To: Brian Rouliston
Cc: Abdul Azam
Subject: RE: Stelazine

Hi Brian,

The new stock has been QA released this morning. I'll notify the wholesalers shortly, pending information regarding subsidy.

Unfortunately the below listing was for Stelazine whereas the brand we're supplying under s29 is the generic name Trifluoperazine. If I submit the pharmacode request immediately, could you push to have that issued immediately and I can complete the NOPC this afternoon?

Kathia Lin
Business Unit Manager, Australasia



From: Brian Rouliston [mailto:]

Sent: Tuesday, 20 September 2016 11:45 AM

To: Kathia Lin < >

Cc: Abdul Azam

Subject: RE: Stelazine

Importance: High

Hi Kathia,

Just a further update, we think that we can get this into the Pharmaceutical Schedule update, subject to getting a Pharmacode for the 112 tab pack presentation. We have a window of one day to get this into the system, as the file for the software vendors will be uploading the Schedule in two days' time.

I see that there was once a 112 tab pack of Stelazine tab 1 mg listed way back in 2006. It had a Pharmacode of 2207516. Would this be the Pharmacode for the new 112 tab pack stock?

- Thiothixene
- Trifluoperazine hydrochloride
- Cap long-acting 15 mg
- Oral liq 1 mg per ml
- Tab 1 mg
- Stelazine Section 29
 - 2207516 (112 tab)
 - Stelazine
 - 256262 (100 tab)
 - 256270 (500 tab)
 - 2243563 (100 tab)
- Tab 2 mg
- Tab 5 mg
- Zephalene

Kind regards,

Brian

From: Brian Rouliston

Sent: Tuesday, 20 September 2016 9:32 a.m.

To: 'Kathia Lin'

Cc: 'Abdul Azam'

Subject: RE: Stelazine

Thanks Kathia,

This is good news. Can you arrange for a Pharmacode for this and send us an NOPC.

At this stage I'm not sure if we'll be able to get this into the Schedule for 1 October or 1 November. In any case hospitals will be able to purchase and use the stock.

Once released, can you let wholesalers know ASAP please.

Couple of other questions.

2mg – can you advise the SOH

5mg – any update, last time I recall that it was thought that a batch would be made in 2016 Q4?

Kind regards,

Brian

From: Kathia Lin [mailto:]

Sent: Friday, 16 September 2016 6:05 p.m.

To: Brian Rouliston

Cc: Abdul Azam

Subject: RE: Stelazine

Hi Brian,

Our shipment of Stelazine 1mg tabs 112's has arrived in New Zealand. We are currently working on QA release. Did you want to consider listing this for subsidy, in the absence of registered Stelazine 1mg stock?

Kathia Lin

Business Unit Manager, Australasia



From: Kathia Lin
Sent: Wednesday, 17 August 2016 10:53 AM
To: 'Brian Rouliston' <[REDACTED]>
Cc: Abdul Azam <[REDACTED]>
Subject: Stelazine

Hi Brian,

To ease the pressure on Stelazine 2mg and the demand for the recently expired 5mg, all our remaining stock of 1mg (exp. Sep-16) are being offered to wholesalers. [REDACTED]
[REDACTED] Upon expiry of this stock, we have been able to access a small quantity of 1mg tablets for immediate import. The supplier has agreed to allocate 300 packs of 112 tablets (approx. 2 months cover), which we will supply under s29 in New Zealand.

We have also transferred 960 packs of Stelazine 2mg from Australia, which is an additional 2-3 months of stock cover. In conjunction with the 203 units on hand, this should last until the end of 2016.

We are still in discussions with the supplier regarding the long term situation with Stelazine. However, it does not seem like we will receive a response on that before the end of the month; we will continue to work on this.

Kathia Lin
Business Unit Manager, Australasia



Level 1, 134 Willoughby Road, Crows Nest NSW 2065, Australia
Tel +612 9431 6333
Fax +612 9906 7147

Email [REDACTED] Web www.concordia.com
Please consider the environment before printing this email.

NOTICE OF CONFIDENTIALITY This e-mail, including all materials contained in or attached to this e-mail, contains proprietary and confidential information solely for the internal use of the intended recipient. If you have received this email in error, please notify us immediately by return e-mail or otherwise and ensure that it is permanently deleted from your systems, and do not print, copy, distribute or read its contents.

Purchase Order System - Suppliers should note that confirmation of orders by any Mercury Pharma or Andipham entity will ONLY be given through a Purchase Order from that entity; see www.concordia.com for more details.

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the system manager.

This footnote also confirms that this email message has been swept by McAfee for the presence of computer viruses.

www.clearswift.com

From: Brian Rouliston
Sent: Tuesday, 20 September 2016 3:46 PM
To: 'Kathia Lin'
Cc: 'Abdul Azam'
Subject: RE: Stelazine

Thanks Kathia, gosh, that Pharmacode came through quickly. We're on track for the listing. The 12th should be fine.

Kind regards,
Brian

From: Kathia Lin [mailto:]
Sent: Tuesday, 20 September 2016 3:31 p.m.
To: Brian Rouliston
Cc: Abdul Azam
Subject: RE: Stelazine

Hi Brian,
Pharmacode came through, please see NOPC enclosed. I've backdated effective date to 12th of this month so please advise if this is not appropriate.
Thanks.



From: Kathia Lin
Sent: Tuesday, 20 September 2016 1:16 PM
To: 'Brian Rouliston'
Cc: Abdul Azam
Subject: RE: Stelazine

Hi Brian,

Application has just been submitted to the Guild. I'll complete NOPC as soon as pharmacode comes through. I've just designated AMCO as the brand name in this case.

Thank you.

Kathia Lin
Business Unit Manager, Australasia

From: Brian Rouliston [mailto:]
Sent: Tuesday, 20 September 2016 12:43 PM
To: Kathia Lin
Cc: Abdul Azam
Subject: RE: Stelazine
Importance: High

Thanks Kathia,

Pharmacode - I've contacted Lisa Cho at the Pharmacy Guild (ph 64-4-) and she will keep a look out for your Pharmacode application and will process this ASAP.

Brand name – generally we don't use chemical names as the brand name, can we use "Boucher" or some other name as the brand name?

Brian

From: Kathia Lin [mailto:]
Sent: Tuesday, 20 September 2016 1:47 p.m.
To: Brian Rouliston
Cc: Abdul Azam
Subject: RE: Stelazine

Hi Brian,

The new stock has been QA released this morning. I'll notify the wholesalers shortly, pending information regarding subsidy.

Unfortunately the below listing was for Stelazine whereas the brand we're supplying under s29 is the generic name Trifluoperazine. If I submit the Pharmacode request immediately, could you push to have that issued immediately and I can complete the NOPC this afternoon?

Kathia Lin

Memorandum for Consideration by Director Operations under Delegated Authority

To: Director Operations
From: Manager, Procurement and Contracts
Date: September 2016

Listing of trifluoperazine hydrochloride (AMCo) tab 1 mg

Recommendations

It is recommended that having regard to the decision criteria set out in Section 2.2 of PHARMAC's Operating Policies and Procedures you exercise your delegated authority and:

resolve to list trifluoperazine hydrochloride tab 1 mg under the brand name AMCo S29 in Section B of the Pharmaceutical Schedule from 1 October 2016 as follows (note prices are ex-manufacturer, excluding GST):

Chemical	Formulation	Brand	Pack size	Price and subsidy
trifluoperazine hydrochloride	Tab 1 mg	AMCo S29	112	\$11.01

resolve to apply the section 29 symbol to the AMCo S29 brand of trifluoperazine hydrochloride tab 1 mg in the 112-tablet pack size in Section B of the Pharmaceutical Schedule from 1 October 2016;

resolve to apply the wastage rule to the AMCoS29 brand of trifluoperazine hydrochloride tab 1 mg in the 112-tablet pack size in Section B of the Pharmaceutical Schedule from 1 October 2016;

note that this listing is proposed due to a shortage of the existing listed 1 mg tablet presentation of Stelazine in the 100-tablet pack size, and;

resolve that consultation on the proposal in this paper was not necessary or appropriate.

Background and analysis

The currently funded Stelazine brand of trifluoperazine hydrochloride 1 mg, 2 mg and 5 mg tablets is supplied by Boucher and Muir, but is not subject to a listing agreement.

In May 2016 Boucher advised of potential supply issue for all presentations of trifluoperazine hydrochloride due to manufacturing delays and the imminent expiry of stock.

Trifluoperazine hydrochloride tablets are indicated in the management of psychotic disorders and acute alcoholism. Several clinicians and pharmacists have contacted PHARMAC staff and raised concern about the shortage.

Existing stock of Stelazine 1 mg expires at the end of September 2016. Boucher has obtained a shipment of alternative AMCo brand 1 mg stock, equivalent to 2 – 3 months' supply. The alternative is in a 112 tab pack and would be supplied under Section 29 of the Medicines Act 1981. This would be supplied at a pro rata price to the existing listed Stelazine tab 1 mg 100 pack. The larger pack size, along with the proposed wastage rule may result in an increase in the volumes claimed.

Boucher has existing stock of the 2 mg presentation to supply the market until the end of 2016, but has no remaining stock of the 5 mg presentation. Boucher has indicated that resupply of the 5 mg strength may occur in late 2016 once the manufacturer completes a batch of stock. PHARMAC staff are communicating with Boucher regarding longer term supply continuity and also plan to take advice from the Mental Health Subcommittee in November regarding how to manage this market in the event that Boucher is not able to supply in the longer term.

Boucher has notified wholesalers of the shortage and will notify of the availability of this alternative stock regardless of whether it is listed. A listing in Section B of the Pharmaceutical Schedule would enable it to be used in hospital outpatient settings where it is commonly dispensed. PHARMAC would communicate to wholesalers and hospital pharmacies regarding the listing.

Total expenditure on trifluoperazine is approximately \$65,000 per year, approximately \$22,000 of which is on the 1 mg presentation. We estimate that the cost to the Combined Pharmaceutical Budget could be \$5,000 (5 year NPV) due to wastage, assumed to be 20%.

From: Kathia Lin <[REDACTED]>
Sent: Tuesday, 25 October 2016 7:42 PM
To: Brian Roulston
Cc: Abdul Azam (Concordia)
Subject: Trifluoperazine

Hi Brian,

As advised today, we are expecting the Australian stock back in our warehouse this week, upon which we'll arrange immediate transfer of 300 units to New Zealand. There may be capacity to allocate more stock once we assess the demand in Australia.

In regards to reason for short supply, the manufacturer of our registered product has unfortunately ceased production due to low volumes. The alternate manufacturer supplies the registered UK product, which is what we're currently supplying under s29. They are happy to continue producing more stock until we can source a new manufacturer for the Australasia market.

At this stage, taking into account API availability and product lead times, the earliest availability of full batch of 1mg and 5mg under s29 will be Q2 of 2017. We await further information from the manufacturer.

Kathia Lin
Business Unit Manager, Australasia



Level 9, 76 Berry Street, North Sydney NSW 2060, Australia
Tel +612 9431 6333
Fax +612 9906 7147

Email [REDACTED] Web www.concordiarx.com

 Please consider the environment before printing this email.

NOTICE OF CONFIDENTIALITY This e-mail, including all materials contained in or attached to this e-mail, contains proprietary and confidential information solely for the internal use of the intended recipient. If you have received this email in error, please notify us immediately by return e-mail or otherwise and ensure that it is permanently deleted from your systems, and do not print, copy, distribute or read its contents.

Purchase Order System - Suppliers should note that confirmation of orders by any Mercury Pharma or Amdipharm entity will ONLY be given through a Purchase Order from that entity; see www.concordiarx.com for more details.

From: Geraldine Macgibbon
Sent: Wednesday, 2 November 2016 9:47 AM
To: Brian Roullston; Andrew Park; Janet Mackay
Cc: Colleen Shramka; Trish Mahoney; Lisa Williams
Subject: RE: Trifluoperazine tablets (Stelazine)

Hi Brian

Many thanks for the updates. I think it would be reasonable for B&M to communicate now to the market what the short term supply situation is. If we get queries then I think we should just say that we're aware of the issue, are working with B&M, and will also be taking advice from the Mental Health Subcom in a few weeks, and we should be in a better position to communicate a longer-term plan after that.

Cheers

Geraldine

From: Brian Roullston
Sent: Wednesday, 26 October 2016 8:50 AM
To: Geraldine Macgibbon ; Andrew Park ; Janet Mackay
Cc: Colleen Shramka ; Trish Mahoney ; Lisa Williams
Subject: RE: Trifluoperazine tablets (Stelazine)

Further information from BNM below :

Questions for us at this stage :
Communications to market - Timing and messages?
Any messages to BNM about continuing to supply etc?

From: Kathia Lin [mailto:]
Sent: Tuesday, 25 October 2016 7:42 p.m.
To: Brian Roullston
Cc: Abdul Azam (Concordia)
Subject: Trifluoperazine

Hi Brian,

As advised today, we are expecting the Australian stock back in our warehouse this week, upon which we'll arrange immediate transfer of 300 units to New Zealand. There may be capacity to allocate more stock once we assess the demand in Australia.

In regards to reason for short supply, the manufacturer of our registered product has unfortunately ceased production due to low volumes. The alternate manufacturer supplies the registered UK product, which is what we're currently supplying under s29. They are happy to continue producing more stock until we can source a new manufacturer for the Australasia market.

At this stage, taking into account API availability and product lead times, the earliest availability of full batch of 1mg and 5mg under s29 will be Q2 of 2017. We await further information from the manufacturer.

Kathia Lin
Business Unit Manager, Australasia

From: Brian Roullston
Sent: Tuesday, 25 October 2016 5:26 p.m.
To: Geraldine Macgibbon; Andrew Park; Janet Mackay
Cc: Colleen Shramka; Trish Mahoney; Lisa Williams
Subject: RE: Trifluoperazine tablets (Stelazine)

Hi

I too was a little surprised at the quick exhaustion of the alternative stock which arrived in mid-September (2 months' supply), but this is perhaps a reflection of the short supply in the market and the quick buy up following previous notifications by BNM and us of a shortage.

Anyway, I just spoke to BNM, they have 2,700 x 112 tab 1mg packs in Australia for both markets. They will allocate 300 packs to NZ (2 months' supply?), currently with packers, NZ ETA late this week/early next week. They are balancing both markets, so there might be more available, but no guarantees.

They have good stock of 2mg, but it is short-dated. 5mg is OOS.

There is no further visibility on additional stock at this stage, but they are going to come back shortly on the longer term situation.

Yes, I didn't want to give BNM any hint that we were considering delisting, I didn't want them to feel relaxed about the current shortage in lieu of a possible delisting! My line has been that these are rather critical patients for whom continuity of supply is important, which they appreciate.

I did say that it might be good to send an update communication to the market. This can come from BNM and focus on the short term supply situation. If we want to hold out until after the 23rd I'm happy with that, but given the noise I think that something sooner would be beneficial. A natural question from the market what is the longer term situation and what is PHARMA doing about it, which might be hard to answer before the 23rd.

Brian

From: Janet Mackay
Sent: Thursday, 20 October 2016 8:50 a.m.
To: Geraldine Macgibbon; Colleen Shramka
Cc: Lisa Williams

Subject: RE: Trifluoperazine tablets (Stelazine)

Perfect – mirrors my preference in terms of any 'implementation' issues that might need to be addressed!

Will wait for an update following the MHSC :)

[SeeMail]

From: Geraldine MacGibbon
Sent: Thursday, 20 October 2016 8:38 a.m.
To: Janet Mackay; Colleen Shramka
Cc: Lisa Williams
Subject: RE: Trifluoperazine tablets (Stelazine)

Hi Janet
That sounds sensible. Colleen is planning on following up with B&M on this and [REDACTED] when Brian is back next week so we should know more soon hopefully.

Having given it further thought I would like to wait until the MHSC has commented on it (nov 23) before we put out any communications, as if (for eg) they think it's vital to have then our message would be that we're working hard to secure supply (and would do so) but if they're relaxed about it being discontinued then our messages would be more around a managed exit from the market and transitioning patients.

Thanks!
Geraldine

[SeeMail]

From: Janet Mackay
Sent: Thursday, 20 October 2016 8:27 a.m.
To: Geraldine MacGibbon; Colleen Shramka
Cc: Lisa Williams
Subject: RE: Trifluoperazine tablets (Stelazine)

Hi there,

I'm thinking some official communication with B&M would probably be the best next step. It's a little tricky to communicate something widely if we haven't heard directly from the supplier about what is happening.

The conversation with B&M could help determine who would do the 'official' communication too.

Cheers,
Janet

[SeeMail]

From: Geraldine MacGibbon
Sent: Tuesday, 18 October 2016 11:53 a.m.
To: Colleen Shramka; Janet Mackay
Cc: Lisa Williams
Subject: FW: Trifluoperazine tablets (Stelazine)

Hi Colleen and Janet please see email trail attached – would appreciate your thoughts on what to do at this point.

It appears that Boucher has run out of its emergency stock, more is on the way for the end of this month. We hadn't done any commits around this because we thought there was some stock that could be used (less than ideal, but still something). I was planning on asking the Mental Health Subcom about this in mid November (along the lines of should we be doing a managed discontinuation of it) but wondering if we should be communicating something earlier. I feel like it should be the company that should do it, but we're not in a very strong position to ask them given that we don't have a contract for it. Even if we did proactively communicate something I'm not really sure what it would say given that we have no idea when or if usual supply is likely to be resumed and we have no options to offer people except suggest that they try and transition their patients onto something else and not put anyone new on it.

I think Brian had been reluctant to talk to B&M about the possibility of notifying an official discontinuation (which would give us something to communicate) while they were focused on bringing in emergency stock and we weren't sure if this was a product we actually vitally need (as we hadn't asked the Subcom yet) but this supply situation just is not going to work so perhaps it is time for Colleen to have that conversation with them?

Thanks
Geraldine

From: Ghada Sarah (ADHB) [mailto:[REDACTED]]
Sent: Tuesday, October 18, 2016 11:25 AM
To: Geraldine MacGibbon <[REDACTED]>
Subject: RE: Trifluoperazine tablets (Stelazine)

Hi Geraldine,

Thanks for your prompt response.

I have been in touch with the company again – [REDACTED] also checked the stock situation of the Jmg S29 product and it wasn't available at two wholesalers (Onelink and PWR)

It would be great if the company or PHARMAAC can send out communications around this issue, as there's a lot of uncertainty and frustration from pharmacists,

clinicians and patients.

Kind regards,
Ghada

Ghada Sarah
Lead Procurement Pharmacist | Ward 41 Pharmacist | Pharmacy Department
[09] 307 4949 ext [redacted] | Mobile [redacted]
Auckland District Health Board | Level 6 | Support Building | Auckland City Hospital | New Zealand

From: Geraldine MacCibbon [mailto:[redacted]]
Sent: Monday, 17 October 2016 5:16 p.m.
To: Ghada Sarah (ADHB)
Subject: RE: Trifluoperazine tablets (Stelazine)

Hi Ghada

I am not sure what is going on here as Boucher advised us on 20 September that it had released the unregistered 1 mg stock to wholesalers (and submitted an NOPC for it on 20 September). It was Kathia Lin ([redacted] Tel [redacted]) who gave us this information. The S29 version was listed on the Pharmaceutical Schedule from 1 October. Have you been unable to purchase this stock from wholesalers? Might be worthwhile contacting Kathia? Unfortunately the person at PHARMAC who was dealing with this is OOO at the moment as am I and I don't want to confuse matters by contacting Kathia myself at this point.

Regarding the other strengths, and registered 1 mg stock, what you have been told pretty much aligns with what we have been told. We are planning to take advice from the Mental Health Subcommittee when it meets in November on the possibility of a managed discontinuation of this product given that we have no supply agreement for it and longer-term supply is highly uncertain.

Perhaps let me know how you get on with the wholesaler and Kathia re S29 1 mg stock and I will follow up when I'm back in the office later tomorrow.

Many thanks
Geraldine

From: Ghada Sarah (ADHB) [mailto:[redacted]]
Sent: Monday, 17 October 2016 2:17 p.m.
To: Geraldine MacCibbon
Subject: RE: Trifluoperazine tablets (Stelazine)
Importance: High

Hi Geraldine,

Sorry to ask again but we are still getting many enquiries about the supply of trifluoperazine. I got in touch with the company this morning to get an update – their reply is copied below for your information.

I think the company's response is very poor and not really acceptable and so I'm hoping you'll be able to follow up with them!

Thanks
Ghada

From: Kelly Sillars [mailto:[redacted]]
Sent: Monday, 17 October 2016 12:56 p.m.
To: Ghada Sarah (ADHB)
Cc: Kathia Lin
Subject: RE: Trifluoperazine tablets (Stelazine)

Good afternoon,

There is a supply issue with Stelazine in all strengths and we don't have any additional information on it or when they will be back in stock.

Stelazine 1mg: We have sourced an alternate product and it should be available by the end of this month
Stelazine 2mg: We have emergency short dated stock, expiry Jan 2017, no of stock update after January.
Stelazine 5mg: No update on if or when the 5mg will be available.

Thank you,

Kelly Sillars
Customer Service Coordinator, Australasia



From: Kathia Lin
Sent: 17 October 2016 08:54 AM
To: Kelly Sillars <[redacted]>
Cc: [redacted]
Subject: FW: Trifluoperazine tablets (Stelazine)
Importance: High

Kelly, can you please provide some information to Ghada on the Stelazine, per her email below? Thanks.

Kathia Lin

From: Ghada Sarah (ADHB) [mailto:]
Sent: Monday, 17 October 2016 7:32 AM
To: Kathia Lih < >
Subject: Trifluoperazine tablets (Stelazine)
Importance: High

Hi Kathia,

Hope you're well.

I'm emailing to enquire about the supply situation with this product as we have been experiencing issues with supply and short dated stock. Our clinicians have also received many phone calls from community pharmacies unable to dispense prescriptions for trifluoperazine.

Can you please let me know what the stock situation is like? And expiry dating of stock currently available? Please advise on all strengths (1mg, 2mg, and 5mg).

Thanks
Ghada

Ghada Sarah
Lead Procurement Pharmacist | Ward 41 Pharmacist | Pharmacy Department
☎ (09) 307 4949 ext | Mobile
Auckland District Health Board | Level 6 | Support Building | Auckland City Hospital | New Zealand

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the system manager.
This footnote also confirms that this email message has been sw ept by
MMSw eeper for the presence of computer viruses.
www.olegswid.com

From: Kathia Lin <[REDACTED]>
Sent: Wednesday, 23 November 2016 12:05 PM
To: Brian Rouleston
Cc: Abdul Azam (Concordia)
Subject: RE: Stock updates - BNM & ABM

Hi Brian,

Thank you for your call and feedback. We will advise as soon as [REDACTED]. I'll also draft up a letter to market regarding Snelazine situation, for your review and comments before we distribute.



From: Kathia Lin
Sent: Tuesday, 22 November 2016 2:18 PM
To: 'Brian Rouleston'
Cc: Abdul Azam (Concordia)
Subject: Stock updates - BNM & ABM

Hi Brian,

Hope you've been well. I'm just writing to advise on stock status for a few product lines:

- [REDACTED]
- Stelazine tablets – 1mg and 5mg stock has since expired as per previous update, and Zmg stock expiring in Jan-17 has now been exhausted through filling orders on a patient requirement basis. We have imported an additional 300 units of Trifluoperazine 1mg (S29) against backorders of 417 units, which we have rationed amongst all wholesalers this morning. There may be an opportunity to import another 300 or so units in December.



Kathia Lin
Business Unit Manager, Australasia
Level 9, 76 Berry Street, North Sydney NSW 2060, Australia
Tel +612 9431 6333
Fax +612 9906 7147
Email [REDACTED] Web www.concordiarx.com
Please consider the environment before printing this email.

NOTICE OF CONFIDENTIALITY This e-mail, including all materials contained in or attached to this e-mail, contains proprietary and confidential information solely for the internal use of the intended recipient. If you have received this email in error, please notify us immediately by return e-mail or otherwise and ensure that it is permanently deleted from your systems, and do not print, copy, distribute or read its contents.

Purchase Order System - Suppliers should note that confirmation of orders by any Mercury Pharma or Amdipharm entity will ONLY be given through a Purchase Order from that entity; see www.concordiarx.com for more details.

From: Geraldine MacGibbon
Sent: Tuesday, September 20, 2016 9:38 AM
To: Ghada Sarah (ADHB)
Subject: RE: Trifluoperazine -supply issues

Hi Ghada

This is our latest update:

1mg – B&M advised late on Friday that stock of Stelazine 1mg S29 had arrived in NZ and was going through QA release. (300 packs, 112 tabs per pack, 2 – 3 months' supply). We need to get this listed in B and are working on it.

2mg - They have brought in stock in August and have enough to last to the end of 2016 – seem to have about 800 packs on hand.

5mg – B&M had previously said that they expected a batch to be manufactured 2016 Q4. It will be out until then.

Longer term supply remains highly uncertain. We are going to take some advice from the Mental Health Subcommittee of PTAC regarding the listing of this product.

Kind regards
Geraldine

From: Ghada Sarah (ADHB) [mailto:]
Sent: Friday, 16 September 2016 9:35 a.m.
To: Geraldine MacGibbon
Subject: RE: Trifluoperazine -supply issues
Importance: High

Hi Geraldine,

We have had several more enquiries now about trifluoperazine, so I'm emailing to find out if there has been any updates? There is no stock of the 5mg, short dated stock (exp 30/9/16) of the 1mg strength & no sign of S29 stock!
We have been relaying the information below but there are on-going concerns from psychiatrists that trifluoperazine is going to go completely out of stock!

Any updates would be much appreciated.

Thanks
Ghada

Ghada Sarah
Lead Procurement Pharmacist | Ward 41 Pharmacist | Pharmacy Department
☎ (09) 307 4949 ext [redacted]

Auckland District Health Board | Level 6 | Support Building | Auckland City Hospital | New Zealand

From: Geraldine MacGibbon [mailto:]
Sent: Thursday, 18 August 2016 9:19 a.m.
To: Ghada Sarah (ADHB)
Subject: RE: Trifluoperazine -supply issues

Hi again Ghada

The latest information I have is that the supplier has managed to secure a little more 2mg stock and a small amount of S29 1mg stock, which combined should get us through until the end of this year. We should have more information on supply beyond that within the next 6 weeks and I will clarify to update you at that time.
Kind regards
Geraldine

From: Geraldine MacGibbon
Sent: Wednesday, 10 August 2016 11:26 a.m.
To: Ghada Sarah (ADHB)
Subject: RE: Trifluoperazine -supply issues

Hi Ghada

The last I heard the supplier was trying to source an alternative (unregistered) presentation for the 1mg and 5mg strengths. I have asked for an update and will get back to you to confirm.

Cheers
Geraldine

From: Ghada Sarah (ADHB) [mailto:]
Sent: Tuesday, 9 August 2016 12:04 p.m.
To: Geraldine MacGibbon
Cc: Janet Mackay
Subject: Trifluoperazine -supply issues

Hi Geraldine,

Thank you for your help with my previous inquiry regarding the [redacted]

I am writing to inform you of trifluoperazine supply issues. In case you haven't been made aware. As far as we're aware there's no 5mg stock as all stock is now expired, 1mg stock will be expiring at the end of Sept, and 2mg will be expiring at the beginning of next year. Our clinicians have received many phone calls from

From: Geraldine MacGibbon
Sent: Tuesday, September 20, 2016 9:37 AM
To: 'Andrew Mckean'
Subject: RE: Trifluoperazine tablets

Hi Andrew

This is the update:

1mg – B&M advised late on Friday that stock of Stelazine 1mg 529 had arrived in NZ and was going through QA release. (300 packs, 112 tabs per pack, 2 – 3 months' supply). We need to get this listed in B and will be working on it.

2mg - They have brought in stock in August and have enough to last to the end of 2016 – seem to have about 800 packs on hand.

5mg – B&M had previously said that they expected a batch to be manufactured 2016 Q4. It will be out until then.

Longer term supply remains highly uncertain. We are going to take some advice from the Mental Health Subcommittee of PTAC regarding the listing of this product.

Kind regards
Geraldine

From: Andrew Mckean [mailto:]
Sent: Tuesday, 20 September 2016 8:21 a.m.
To: Geraldine MacGibbon
Subject: FW: Trifluoperazine tablets

Hi Geraldine

Sorry to yet again be asking you about this, but is there any update from the drug company about the availability of trifluoperazine tablets? We continue to have had enquiries from community pharmacies unable to source it from CDC or Propharma. As an aside, we have located a source (MedSurge) in Australia who has stock (see below).

With warmest regards

Andrew Mckean
Senior Pharmacist
Hillmorton Hospital
Private Bag 4733
Christchurch
Phone (internal) [redacted]

From: Yvonne McBrearty
Sent: Tuesday, 20 September 2016 7:39 a.m.
To: Andrew Mckean <[redacted]>
Subject: FW: Trifluoperazine tablets

Hi Andrew,
Quotes below from Australia.
Do you wish me to purchase any for you?

Regards
Yvonne

Purchasing Officer
Pharmacy Services
Christchurch Hospital
2 Riccarton Ave
Christchurch 8011
New Zealand

Phone: [redacted]
Email: [redacted]

Internal



From: Geraldine MacGibbon
Sent: Wednesday, October 19, 2016 3:03 PM
To: 'Ghada Sarah (ADHB)'
Subject: RE: Trifluoperazine tablets (Stelazine)

Hi Ghada

Once we've had a chance to meet with the supplier and take some advice from the Mental Health Subcommittee we'll be in a better position to communicate with the market. Due to the last minute nature of the S29 listing we missed the last update notification otherwise the stock shortage and (hopefully) temporary listing would have been included.

The information you've shared with us will be helpful when we meet with the supplier so many thanks for that.

Kind regards
Geraldine

From: Ghada Sarah (ADHB) [mailto:]
Sent: Tuesday, 18 October 2016 11:25 a.m.
To: Geraldine MacGibbon
Subject: RE: Trifluoperazine tablets (Stelazine)

Hi Geraldine,

Thanks for your prompt response.

I have been in touch with the company again – email attached for your information. I also checked the stock situation of the 1mg S29 product and it wasn't available at two wholesalers (Onelink and PWRJ)

It would be great if the company or PHARMAAC can send out communications around this issue, as there's a lot of uncertainty and frustration from pharmacists, clinicians and patients.

Kind regards,
Ghada

Ghada Sarah
Lead Procurement Pharmacist | Ward 41 Pharmacist | Pharmacy Department
☎ (09) 307 4949 ext [redacted]
Auckland District Health Board | Level 6 | Support Building | Auckland City Hospital | New Zealand

From: Geraldine MacGibbon [mailto:]
Sent: Monday, 17 October 2016 5:16 p.m.
To: Ghada Sarah (ADHB)
Subject: RE: Trifluoperazine tablets (Stelazine)

Hi Ghada

I am not sure what is going on here as Boucher advised us on 20 September that it had released the unregistered 1 mg stock to wholesalers (and submitted an NOPC for it on 20 September). It was Kathia Lin [redacted] who gave us this information. The S29 version was listed on the Pharmaceutical Schedule from 1 October. Have you been unable to purchase this stock from wholesalers? Might be worthwhile contacting Kathia? Unfortunately the person at PHARMAAC who was dealing with this is OOO at the moment as am I and I don't want to confuse matters by contacting Kathia myself at this point.

Regarding the other strengths, and registered 1 mg stock, what you have been told pretty much aligns with what we have been told. We are planning to take advice from the Mental Health Subcommittee when it meets in November on the possibility of a managed discontinuation of this product given that we have no supply agreement for it and longer-term supply is highly uncertain.

Perhaps let me know how you get on with the wholesaler and Kathia re S29 1 mg stock and I will follow up when I'm back in the office later tomorrow.

Many thanks
Geraldine

From: Ghada Sarah (ADHB) [mailto:]
Sent: Monday, 17 October 2016 2:17 p.m.
To: Geraldine MacGibbon
Subject: RE: Trifluoperazine tablets (Stelazine)
Importance: High

Hi Geraldine,

Sorry to ask again but we are still getting many enquiries about the supply of trifluoperazine. I got in touch with the company this morning to get an update – their reply is copied below for your information.

I think the company's response is very poor and not really acceptable and so I'm hoping you'll be able to follow up with them!

Thanks
Ghada

From: Kelly Sillars [mailto:]
Sent: Monday, 17 October 2016 12:56 p.m.
To: Ghada Sarah (ADHB)
Cc: Kathia Lin
Subject: RE: Trifluoperazine tablets (Stelazine)

Good afternoon,

There is a supply issue with Stelazine in all strengths and we don't have any additional information on if or when they will be back in stock.
Stelazine 1mg: We have sourced an alternate product and it should be available by the end of this month
Stelazine 2mg: We have emergency short dated stock, expiry Jan 2017, no of stock update after January.
Stelazine 5mg: No update on if or when the 5mg will be available.
Thank you,

Kelly Sillars
Customer Service Coordinator, Australasia



From: Kathia Lin
Sent: 17 October 2016 08:54 AM
To: Kelly Sillars <[REDACTED]>
CC: [REDACTED]
Subject: FW: Trifluoperazine tablets (Stelazine)
Importance: High

Kelly, can you please provide some information to Ghada on the Stelazine, per her email below? Thanks.

Kathia Lin
Business Unit Manager, Australasia



From: Ghada Sarah (ADHB) [mailto:[REDACTED]]
Sent: Monday, 17 October 2016 7:32 AM
To: Kathia Lin <[REDACTED]>
Subject: Trifluoperazine tablets (Stelazine)
Importance: High

Hi Kathia,

Hope you're well.

I'm emailing to enquire about the supply situation with this product as we have been experiencing issues with supply and short dated stock. Our clinicians have also received many phone calls from community pharmacies unable to dispense prescriptions for trifluoperazine.
Can you please let me know what the stock situation is like? And expiry dating of stock currently available? Please advise on all strengths (1mg, 2mg, and 5mg).

Thanks
Ghada

Ghada Sarah
Lead Procurement Pharmacist | Ward 41 pharmacist | Pharmacy Department
[REDACTED]

Auckland District Health Board | Level 6 | Support Building | Auckland City Hospital | New Zealand


This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the system manager.
This footnote also confirms that this email message has been swept by McAfee eppor for the presence of computer viruses.
www.chestny.it (EN)

From: Grace Carr
Sent: Wednesday, December 21, 2016 11:15 AM
To: Victoria London
Subject: FW: Trifluoperazine tablets (Stelazine)

From: Kathia Lin [mailto: [REDACTED]]
Sent: Tuesday, October 18, 2016 10:46 AM
To: Ghada Sarah (ADHB) < [REDACTED] >; Kelly Sillars < [REDACTED] >
Subject: RE: Trifluoperazine tablets (Stelazine)

Hi Ghada,

Unfortunately we have no visibility on the long term situation of the registered products, as the supplier is sorting out the issues with the manufacturer. We have run out of the initial lot of the 1mg (s29) stock [REDACTED] discussions to import further s29 stocks of both the 1mg and 5mg, but that may not happen until Q2 2017.

Kathia Lin
Business Unit Manager, Australasia
 **CONCORDIA**
INTERNATIONAL


From: Ghada Sarah (ADHB) [mailto: [REDACTED]]
Sent: Tuesday, 18 October 2016 8:23 AM
To: Kelly Sillars ; Kathia Lin
Subject: RE: Trifluoperazine tablets (Stelazine)
Importance: High

Hi Kelly and Kathia,

Can you clarify if the 1mg (s29) stock is currently available for purchase? as I just checked with 2 wholesalers and both don't have stock? also is the arrangement with supplying alternate 1mg s29 tabs a long term one, or just during the shortage?

Can you comment about the long term supply of other strengths?

We need to inform the clinicians ASAP if there is no supply long term so they start managing patients accordingly and switch to alternatives!

Ghada Sarah
Lead Procurement Pharmacist | Ward 41 Pharmacist | Pharmacy Department
 [REDACTED]
Auckland District Health Board | Level 6 | Support Building | Auckland City Hospital | New Zealand

From: Kelly Sillars [mailto: [REDACTED]]
Sent: Monday, 17 October 2016 12:56 p.m.
To: Ghada Sarah (ADHB)
Cc: Kathia Lin
Subject: RE: Trifluoperazine tablets (Stelazine)

Good afternoon,

There is a supply issue with Stelazine in all strengths and we don't have any additional information on if or when they will be back in stock.
Stelazine 1mg: We have sourced an alternate product and it should be available by the end of this month
Stelazine 2mg: We have emergency short dated stock, expiry Jan 2017, no of stock update after January.
Stelazine 5mg: No update on it or when the 5mg will be available.
Thank you,

Kelly Sillars
Customer Service Coordinator, Australasia



From: Kathia Lin
Sent: 17 October 2016 08:54 AM
To: Kelly Sillars < [REDACTED] >
Cc: [REDACTED]
Subject: FW: Trifluoperazine tablets (Stelazine)
Importance: High

Kelly, can you please provide some information to Ghada on the Stelazine, per her email below? Thanks.
Kathia Lin



Business Unit Manager, Australasia

From: Ghada Sarah (ADHB) [mailto: [REDACTED]]
Sent: Monday, 17 October 2016 7:32 AM
To: Kathia Lin < [REDACTED] >
Subject: Trifluoperazine tablets (Stelazine)
Importance: High

Hi Kathia,

Hope you're well.

I'm emailing to enquire about the supply situation with this product as we have been experiencing issues with supply and short dated stock. Our clinicians have also received many phone calls from community pharmacies unable to dispense prescriptions for trifluoperazine.

Can you please let me know what the stock situation is like? And expiry dating of stock currently available? Please advise on all strengths (1mg, 2mg, and 5mg).

Thanks
Ghada

Ghada Sarah
Lead Procurement Pharmacist | Ward 41 Pharmacist | Pharmacy Department
Auckland District Health Board | Level 6 | Support Building | Auckland City Hospital | New Zealand

From: Brian Rouliston
Sent: Thursday, October 13, 2016 9:09 AM
To: 'Kathia Lin'
Subject: FW: Stelazine (trifluoperazine) - brand name

Thanks Kathia

From: Kathia Lin [mailto:Kathia.Lin@concordia.rg.com]
Sent: Thursday, 13 October 2016 12:34 a.m.
To: Brian Rouliston
Cc: Abdul Azam (Concordia)
Subject: RE: Stelazine (trifluoperazine) - brand name

Hi Brian,

Thank you for your comments. I can see why this would be confusing for patients and agree that Mercury Pharma may be more appropriate. I have enclosed our NOPC to this effect.

In addition, I have enclosed 3 other NOPCs that were meant to be sent today. My apologies for the lateness. I had completely forgotten after drafting them. We would be grateful if you kindly process all 4 to be included in the 1 November schedule.

Thank you.

Kathia Lin
Business Unit Manager, Australasia



From: Brian Rouliston [mailto:]
Sent: Wednesday, 12 October 2016 8:51 AM
To: Kathia Lin
Cc: Abdul Azam (Concordia)
Subject: RE: Stelazine (trifluoperazine) - brand name

Hi Kathia,

Just regarding the brand name, we've had some feedback that the brand name of 'AMCo' is somewhat confusing as the name 'Mercury Pharma' is on the box as the manufacturer. It's been suggested that it would be better to list the brand as 'Mercury Pharma'. Do you have a view on this?

If you're comfortable with 'Mercury Pharma' as the brand name then we can amend this in the Pharmaceutical Schedule from 1 November. Just send us an NOPC today to confirm the name change.

<https://www.pharma.govt.nz/assets/notifications/production-of-product-changes.pdf>

Just send us an NOPC today to

Kind regards,
Brian

From: Kathia Lin
Sent: Tuesday, 20 September 2016 1:16 PM
To: 'Brian Rouliston'
Cc: Abdul Azam
Subject: RE: Stelazine

Hi Brian,

Application has just been submitted to the Guild. I'll complete NOPC as soon as Pharmacode comes through. I've just designated AMCo as the brand name in this case. We have pro-rated the sell price so the subsidy you have suggested will be sufficient.

Thank you.

Kathia Lin
Business Unit Manager, Australasia



From: Brian Rouliston [mailto:]
Sent: Tuesday, 20 September 2016 12:43 PM
To: Kathia Lin

Cc: Abdul Azam
Subject: RE: Stelazine
Importance: High

Thanks Kathia,

Pharmacode - I've contacted Lisa Cho at the Pharmacy Guild and she will keep a look out for your Pharmacode application and will process this ASAP.

Brand name - generally we don't use chemical names as the brand name, can we use "Boucher" or some other name as the brand name?
Subsidy - Happy to discuss, but the [REDACTED]

Brian

From: Kathia Un [mailto:[REDACTED]]
Sent: Tuesday, 20 September 2016 1:47 p.m.
To: Brian Rouiston
Cc: Abdul Azam
Subject: RE: Stelazine

Hi Brian,

The new stock has been QA released this morning. I'll notify the wholesalers shortly. Pending information regarding subsidy. Unfortunately the below listing was for Stelazine whereas the brand we're supplying under s29 is the generic name Trifluoperazine. If I submit the pharmacode request immediately, could you push to have that issued immediately and I can complete the NOPC this afternoon?

Kathia Un
Business Unit Manager, Australasia



From: Brian Rouiston [mailto:[REDACTED]]
Sent: Tuesday, 20 September 2016 11:45 AM
To: Kathia Un
Cc: Abdul Azam
Subject: RE: Stelazine
Importance: High

Hi Kathia,

Just a further update, we think that we can get this into the Pharmaceutical Schedule update, subject to getting a pharmacode for the 112 tab pack presentation. We have a window of one day to get this into the system, as the file for the software vendors will be uploading the Schedule in two days' time. I see that there was once a 112 tab pack of Stelazine tab 1mg listed way back in 2006. It had a Pharmacode of 2207516. Would this be the Pharmacode for the new 112 tab pack stock?

- Thioklene
- Trifluoperazine hydrochloride
- Cap longacting 15 mg
- Dial liq 1 mg per ml
- Tab 1 mg
- Stelazine Section 29
- Stelazine
- 2207516 (112 tab)
- 255262 (100 tab)
- 255270 (500 tab)
- 2243563 (100 tab)
- Tab 2 mg
- Tab 5 mg
- Zovatsolone

Kind regards,
Brian

From: Brian Rouiston
Sent: Tuesday, 20 September 2016 9:32 a.m.
To: Kathia Un
Cc: Abdul Azam
Subject: RE: Stelazine

Thanks Kathia,

This is good news. Can you arrange for a Pharmacode for this and send us an NOPC. With a pack size of 112, the listing and subsidy would be \$11.01.

At this stage I'm not sure if we'll be able to get this into the Schedule for 1 October or 1 November. In any case hospitals will be able to purchase and use the stock.

Once released, can you let wholesalers know ASAP please.

Couple of other questions,

2mg – can you advise the SOH

5mg – any update, last time I recall that it was thought that a batch would be made in 2016 Q4?

Kind regards,

Brian

From: Kathia Lin [mailto:]
Sent: Friday, 16 September 2016 6:05 p.m.
To: Brian Rouliston
Cc: Abdul Azam
Subject: RE: Stelazine

Hi Brian,

Our shipment of Stelazine 1mg tabs 112's has arrived in New Zealand. We are currently working on QA release. Did you want to consider listing this for subsidy, in the absence of registered Stelazine 1mg stock?



From: Kathia Lin
Sent: Wednesday, 17 August 2016 10:53 AM
To: 'Brian Rouliston' < >
Cc: Abdul Azam < >
Subject: Stelazine

Hi Brian,

To ease the pressure on Stelazine 2mg and the demand for the recently expired 5mg, [REDACTED] Upon expiry of this stock, we have been able to access a small quantity of 1mg tablets for immediate import. The supplier has agreed to allocate 300 packs of 112 tablets (approx. 2 months cover), which we will supply under s29 in New Zealand.

We have also transferred 960 packs of Stelazine 2mg from Australia, which is an additional 2-3 months of stock cover. In conjunction with the 203 units on hand, this should last until the end of 2016.

We are still in discussions with the supplier regarding the long term situation with Stelazine. However, it does not seem like we will receive a response on that before the end of the month, we will continue to work on this.

Kathia Lin
Business Unit Manager, Australasia



Level 1, 134 Willoughby Road, Crows Nest NSW 2065, Australia
Tel +612 9431 6333
Fax +612 9906 7147
Email [REDACTED] Web www.concordiarx.com

 Please consider the environment before printing this email.

NOTICE OF CONFIDENTIALITY This e-mail, including all materials contained in or attached to this e-mail, contains proprietary and confidential information solely for the internal use of the intended recipient. If you have received this email in error, please notify us immediately by return e-mail or otherwise and ensure that it is permanently deleted from your systems, and do not print, copy, distribute or read its contents.

Purchase Order System - Suppliers should note that confirmation of orders by any Mercury Pharma or Amdipharm entity will ONLY be given through a Purchase Order from that entity; see www.concordiarx.com for more details.

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the system manager.
This footnote also confirms that this email message has been swept by McAfee VirusScan for the presence of computer viruses.
www.mcafee.com

From: Web Enquiry
Sent: Wednesday, 29 June 2016 12:45 PM
To: 'Liddell Marcus'
Subject: RE: Stelazine

Dear Ayshta,

Thank you for your recent enquiry regarding repeats on Stelazine.

It is acceptable to change the strength of the medication Stelazine to the 2mg tablet and adjust the instructions accordingly on subsequent repeats, now that the 2mg tablets back in stock. These repeats will still be eligible for subsidy.

It is not necessary to obtain a new prescription from the prescriber in this case.

I hope this information was helpful and please feel free to ask me any further questions you may have on this matter.

Kind Regards,

Juanita Galuszka
PHARMAC

From: Liddell Marcus [mailto:]
Sent: Friday, 24 June 2016 12:46 PM
To: Web Enquiry < >
Subject: Stelazine

Hi Pharmac,

We have some people who are on Stekazine 2mg as a dose. I can't quite remember when, but at some point we couldn't get the 2mg tablets, so had to switch them to the 1mg tablets and the instructions to Take TWO tablets. Now the 1mg is unavailable, but the 2mg is available. Can we switch to the 2mg strength on the repeats and adjust the instructions and still get paid, like we do with the Metoprolol, or will we have to ask the prescriber for new prescriptions?

Many thanks,
Ayshta, Technician at Ors Dargaville

CAUTION: This e-mail message and accompanying data may contain information that is confidential and subject to privilege. If you are not the intended recipient, you are notified that any use, dissemination, distribution or copying of this message or data is prohibited. If you have received this e-mail in error, please notify the sender immediately and delete all material pertaining to this e-mail. Dargaville Ors Pharmacy will not accept liability for any loss or damage caused by using any material or attachments contained in this message. While every best practice has been taken, no warranty is made that this material is free from computer virus or other defect. Dargaville Ors Pharmacy's entire liability will be limited to resupplying the material.

From: Web Enquiry
Sent: Tuesday, 1 November 2016 3:00 PM
To: [REDACTED]
Subject: Stelazine tablets

Dear Belinda

Thank you for your call regarding Stelazine. At present, the 2 mg tablets are in stock and available in pharmacies, however, the 1 mg and 5 mg tablets are currently out of stock nationwide. As such, we have sourced an alternative brand of trifluperazine 1 mg tablets which are available in pharmacies fully subsidised. Please note that there is no alternative replacement product for the 5 mg tablets at this time.

In the first instance, we suggest your mother-in-law discuss her concerns with her doctor. They will be best placed to advise her on her treatment options, including consideration of whether one of the other funded medicines might be an option for her.

I hope this is helpful, please get back in touch if there is anything else I can help you with.

Kind regards
Doris Chong
PHARMAAC

From: Web Enquiry
Sent: Tuesday, 6 December 2016 10:36 AM
To: 'Dr Douglas Horne'
Subject: RE: trifluoperazine

Dear Douglas

Thank you for your email regarding trifluoperazine.

The supplier of Stelazine, Boucher and Muir, has notified PHARMAC that the manufacture of the Stelazine brand of trifluoperazine hydrochloride has been discontinued.

Boucher and Muir are sourcing alternatives and a limited supply of an alternative brand, Mercury Pharma, has recently been distributed to wholesalers; however only a 1mg tab presentation is available under Section 29 of the Medicines Act (S29). While we are working with Boucher to ensure continuity of supply, there remains considerable uncertainty regarding the longer term supply situation.

New patients should be started on alternative treatments and prescribers should consider switching existing patients to alternative treatments as soon as possible.

I hope this has answered your question.

Kind regards
Doris Chong
PHARMAC

From: Dr Douglas Horne [mailto:]
Sent: Tuesday, 29 November 2016 2:17 PM
To: Web Enquiry < >
Subject: trifluoperazine

Dear Pharmac.

Does Pharmac have any advice in regards to the national shortage of stelazine (trifluoperazine).
Because of the nature of this medicine , there is potential for harm if we switch patients to a different antipsychotic. The majority of patients that we have on this medication have been on it for 20+ years.
? what is the recommended advice for an alternative, and ? how long is the shortage expected to last.

Yours sincerely
Dr Douglas Horne
Clinical Director
Westview medical Centre
Glen Eden
Auckland.

From: Donna Jennings on behalf of Web Enquiry
Sent: Tuesday, 11 October 2016 4:45 PM
To: 'Esther Abeln'
Subject: RE: trifluoperazine

Dear Esther

Thank you for your email to Sarah Fitt regarding the current supply issues with trifluoperazine.

The supply issues do not currently affect the 2 mg strength.

There are currently supply issues with the 1 mg and 5 mg strengths only. We have listed an alternative brand of the 1 mg strength, however, there is no alternative replacement product for the 5 mg at this time.

Please let me know if you need any further information.

Kind regards
Donna Jennings
PHARMMAC

From: Esther Abeln [mailto:████████████████████]
Sent: Thursday, October 6, 2016 10:24 AM
To: Web Enquiry <enquiry@Pharmac.govt.nz>
Subject: trifluoperazine

To Sarah Fitt

Dear Sarah

I have seen the pharmac note to pharmacies about supplies of trifluoperazine.

However, I am not sure I fully understand the meaning.

Can you confirm that 2 mg Stelazine tablets will continue to be available without any supply issues?

Many thanks for your help

Best regards

Esther Abeln | Consultant Psychiatrist | Mental Health Service for Older People | Southern DHB | Dunedin Hospital
Private Bag 1821, Dunedin 9094, New Zealand | office: ████████████████████

This email or attachments may contain confidential or legally privileged information intended for the sole use of the addressee(s). Any use, redistribution, disclosure, or reproduction of this message, except as intended, is prohibited. If you received this email in error, please notify the sender and remove all copies of the message, including any attachments. Please note, the views expressed in this communication are not necessarily those of the Southern DHB, unless expressly so stated or apparent from the context.

From: [REDACTED]
Sent: Friday, 16 December 2016 11:11 AM
To: Web Enquiry
Cc: Jacky Robinson
Subject: trifluoperazine 1 or 2mg

pharmac
cc: PML

Please advise-
URGENTLY!

We have been unable to obtain any brand Sblazte or Trifluoperazine from our wholesalers PML

Despite regularly phoning and e-mailing Concordia AMCo Mercury we have not been able to get any information

We have a Sed29 order on backorder since this product was advised

We have a patient for whom this will become a huge issue should we not be able to obtain any stock any strength before Christmas

Please advise

Regards

Gary Logan

 *garyloganpharmacy*

Confidential- May Contain Medical Information.

Please Respect Privacy.

Do Not Forward unless you have our written Authority.

Please consider the environment do not print unnecessarily

Please advise and delete if you have received this message in error.

gary logan pharmacy
121 King Street
Pukekohe 2120
[REDACTED]

From: [REDACTED]
Sent: Friday, November 25, 2016 11:42 AM
To: Web Enquiry
Subject: Stelazine discontinuation

Hi,
I have been informed by my wholesaler that Stelazine has been discontinued, and this was confirmed with PHARMAC. Do you have a notification regarding this? I have a number of patients on it and I need to inform their prescribers ASAP.

Many thanks

Katt George
Pharmacist

QualMed Pharmacy
Phone: [REDACTED]

CAUTION: This message is intended for the use of the individual to whom it is addressed and may contain information that is confidential, privileged and exempt from disclosure under applicable law. If you are not the intended recipient, please advise the sender immediately and delete the email and attachments. Any use, dissemination, reproduction or distribution of this email and any attachments by anyone other than the intended recipient is prohibite

From: Marton Pharmacy Manager <[REDACTED]>
Sent: Thursday, November 24, 2016 2:57 PM
To: Web Enquiry
Subject: Stelazine

Could you please tell me what alternative is being put in place for patients who are on Stelazine. We have enough to get our patient thru until mid-January, but want to know if there will be an alternative by then or if we should get his doctor to start changing him to an alternative.

Thank you

Trudi Tutty

--

Trudi Tutty
Pharmacist

Manager Marton Pharmacy
292 Broadway
Marton

**Excerpt from
The Mental Health Subcommittee of PTAC Memorandum
November 2016**

- See below for in scope information regarding the management of Stelazine (trifluoperazine) supply

Discontinuations

PHARMAAC has been notified of discontinuation or supply issues with a number of antipsychotics.

- Trifluoperazine hydrochloride (Stelazine) tab 1 mg, 2 mg and 5 mg has had significant supply issues recently, with only short-dated and unregistered stock of the 1 mg and 2 mg currently available and no 5 mg stock available. The supplier has been unable to confirm security of long term supply. Approximately 700-800 people per year take funded trifluoperazine, with a normal age distribution.

Questions to the Subcommittee

17. Given the considerable uncertainty around long-term supply of trifluoperazine tablets, would the Subcommittee be supportive of a managed transition to discontinuation of this product? This would involve providing about 12 months' notice of PHARMAAC's intention to delist the product, restricting its use to existing patients only and writing to prescribers to ask them to start transitioning patients to another treatment.
18. Other than for existing patients, is there any clinical need for trifluoperazine tablets that cannot be met by other funded treatments? What other funded treatments provide similar therapeutic benefit?